Use of Inhaled Iloprost in an Infant With Bronchopulmonary Dysplasia and Pulmonary Artery Hypertension

다국어 초록 (Multilingual Abstract)

Pulmonary artery hypertension is a common cardiovascular complication in preterm infants with bronchopulmonary
dysplasia which is associated with increased morbidity and mortality. Inhaled iloprost is used as a therapeutic
option in pulmonary hypertension, especially in adults. There have been but a few reports on the use of iloprost for
neonates and infants. We report the case of a 5 month-old-male infant who received neonatal intensive care for
4 months due to respiratory distress syndrome and prematurity, during which he developed bronchopulmonary
dysplasia. Echocardiography showed severe pulmonary hypertension. The initial treatment included respiratory
support with high frequency oscillatory ventilation (HFOV); however, his clinical condition did not improve. Inhaled
iloprost with sildenafil, an oral phosphodiesterase-5 inhibitor, was thus used. With the administration of
iloprost and sildenafil, his condition improved and he was weaned from oxygen. Our clinical experience suggests
that iloprost is a promising therapy for pulmonary hypertension, especially when inhaled nitric oxide is unavailable.

다국어 초록 (Multilingual Abstract)

Pulmonary artery hypertension is a common cardiovascular complication in preterm infants with bronchopulmonary
dysplasia which is associated with increased morbidity and mortality. Inhaled iloprost is used as a therapeutic
option in pulmonary hypertension, especially in adults. There have been but a few reports on the use of iloprost for
neonates and infants. We report the case of a 5 month-old-male infant who received neonatal intensive care for
4 months due to respiratory distress syndrome and prematurity, during which he developed bronchopulmonary
dysplasia. Echocardiography showed severe pulmonary hypertension. The initial treatment included respiratory
support with high frequency oscillatory ventilation (HFOV); however, his clinical condition did not improve. Inhaled
iloprost with sildenafil, an oral phosphodiesterase-5 inhibitor, was thus used. With the administration of
iloprost and sildenafil, his condition improved and he was weaned from oxygen. Our clinical experience suggests
that iloprost is a promising therapy for pulmonary hypertension, especially when inhaled nitric oxide is unavailable.

참고문헌 (Reference)

1 McLaughlin VV, "Survival in primary pulmonary hypertension: the impact of epoprostenol therapy" 106 : 1477-1482, 2002

2 Ivy DD, "Short-and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension" 51 : 161-169, 2008

3 Rashid A, "Pulmonary hypertension in children" 16 : 237-247, 2006

4 Beghetti M, "Pulmonary hypertension associated with congenital heart disease" 23 (23): 13S49-13S59, 2006

5 Khemani E, "Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era" 120 : 1260-1269, 2007

6 Berman Rosenzweig E, "Pulmonary arterial hypertension: a comprehensive review of pharmacological treatment" 5 : 117-127, 2006

7 김형우, "Pulmonary Arterial Hypertension in Children:A Single Center Experience" 대한심장학회 38 (38): 644-650, 2008

8 Abman SH, "Monitoring cardiovascular function in infants with chronic lung disease of prematurity" 87 : F15-F18, 2002

9 Sitbon O, "Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: progonostic factors and survival" 40 : 780-788, 2002

10 Galiè N, "Guidlines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology" 25 : 2243-2278, 2004